Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis.

In addition, trial-level summary data may not have been adequately powered to detect differences between products—for example, while randomised controlled studies of Gla-100 versus Gla-300 and pooled patient level data from these studies have shown that Gla-300 is associated with a significantly lower rate of nocturnal hypoglycaemia, the trial-level data comparisons in this NMA did not achieve significance for this end point.

also in 1,397 other papers